2000年のEBCTCGの概要:広がるギャップ

Same author

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Breast (Edinburgh, Scotland)·2026

Same author

The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.

Cancer treatment reviews·2026

Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Breast (Edinburgh, Scotland)·2026

Same author

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025

Same author

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

関連する実験動画

2000年のEBCTCGの概要:広がるギャップ

関連する概念動画

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

関連する実験動画

2000年のEBCTCGの概要:広がるギャップ

関連する概念動画

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

関連する実験動画

2000年のEBCTCGの概要:広がるギャップ

関連する概念動画

関連記事

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

関連する実験動画

2000年のEBCTCGの概要:広がるギャップ

関連する概念動画

関連記事

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.